Form 8-K Revance Therapeutics, For: Feb 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Revance Therapeutics (RVNC) Tops Q4 EPS by 9c
February 28, 2022 4:36 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.93), $0.09 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.27 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More